ANIP · Insider Trading
ANI Pharmaceuticals, Inc.
Every open-market purchase and sale reported by ANIP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$36.80K |
| 2026-09-30 | Stephen P. Carey | SVP & CFO | Sell | −2,850 | −$208.05K |
| 2026-09-16 | Nikhil Lalwani | PRESIDENT & CEO | Sell | −5,400 | −$383.40K |
| 2026-09-14 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$35.40K |
| 2026-09-14 | Jeanne Thoma | Director | Sell | −1,000 | −$71.53K |
| 2026-09-01 | Stephen P. Carey | SVP & CFO | Sell | −2,850 | −$207.48K |
| 2026-08-27 | Henry O Gosebruch | Director | A | +6,662 | — |
| 2026-08-26 | Nikhil Lalwani | PRESIDENT & CEO | Sell | −5,400 | −$401.22K |
| 2026-08-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$37.74K |
| 2026-08-11 | Ori Gutwerg | SVP, GENERICS | Sell | −3,162 | −$243.47K |
| 2026-07-30 | Stephen P. Carey | SVP & CFO | Sell | −2,850 | −$231.88K |
| 2026-07-21 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | F | −2,466 | −$195.31K |
| 2026-07-14 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$40.92K |
| 2026-07-06 | Stephen P. Carey | SVP & CFO | MIXED | — | −$120.89K |
| 2026-06-15 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$41.02K |
| 2026-06-10 | Jeanne Thoma | Director | A | +4,357 | — |
| 2026-06-10 | Matthew J Leonard | Director | A | +4,357 | — |
| 2026-06-10 | Antonio R Pera | Director | A | +4,357 | — |
| 2026-06-10 | Thomas Haughey | Director | MIXED | +2,357 | −$161.76K |
| 2026-06-10 | Renee P Tannenbaum | Director | A | +4,357 | — |
| 2026-06-09 | Stephen P. Carey | SVP & CFO | MIXED | — | −$100.98K |
| 2026-05-13 | Nikhil Lalwani | PRESIDENT & CEO | Sell | −55,000 | −$4.27M |
| 2026-05-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$39.08K |
| 2026-05-13 | Patrick D Walsh | Director | Sell | −13,973 | −$1.13M |
| 2026-05-13 | Ori Gutwerg | SVP, GENERICS | Sell | −2,772 | −$220.37K |
| 2026-05-13 | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | Sell | −459 | −$36.36K |
| 2026-04-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$38.98K |
| 2026-03-13 | Christopher Mutz | HEAD OF RARE DISEASE | Sell | −3,162 | −$226.53K |
| 2026-03-13 | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | Sell | −4,772 | −$357.47K |
| 2026-03-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | −500 | −$36.31K |
| 2026-03-10 | Stephen P. Carey | SVP & CFO | F | −5,150 | −$381.31K |
| 2026-03-10 | Ori Gutwerg | SVP, GENERICS | F | −3,314 | −$245.37K |
| 2026-03-10 | Nikhil Lalwani | PRESIDENT & CEO | F | −17,060 | −$1.26M |
| 2026-03-10 | Krista Davis | SVP, CHIEF HR OFFICER | Sell | −6,572 | −$488.47K |
| 2026-03-10 | Christopher Mutz | HEAD OF RARE DISEASE | MIXED | −9,037 | −$669.99K |
| 2026-03-05 | Stephen P. Carey | SVP & CFO | MIXED | −4,000 | −$388.05K |
| 2026-03-04 | Christopher Mutz | HEAD OF RARE DISEASE | Sell | −417 | −$30.86K |
| 2026-03-04 | Ori Gutwerg | SVP, GENERICS | Sell | −2,060 | −$157.59K |
| 2026-03-03 | Patrick D Walsh | Director | Sell | −6,000 | −$445.38K |
| 2026-03-02 | Christopher Mutz | HEAD OF RARE DISEASE | MIXED | +19,085 | +$1.48M |
| 2026-03-02 | Ori Gutwerg | SVP, GENERICS | MIXED | +10,748 | +$836.43K |
| 2026-03-02 | Nikhil Lalwani | PRESIDENT & CEO | MIXED | +63,375 | +$4.93M |
| 2026-03-02 | Stephen P. Carey | SVP & CFO | MIXED | +19,460 | +$1.51M |
| 2026-03-02 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | A | +11,116 | +$857.60K |
| 2026-03-02 | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | MIXED | +5,393 | +$418.11K |
| 2026-03-02 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | MIXED | +8,895 | +$693.47K |
| 2026-03-02 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | MIXED | +12,340 | +$957.08K |
| 2026-03-02 | Krista Davis | SVP, CHIEF HR OFFICER | MIXED | +9,255 | +$719.08K |
| 2026-02-23 | Krista Davis | SVP, CHIEF HR OFFICER | Sell | −3,814 | −$296.50K |
| 2026-02-23 | Christopher Mutz | HEAD OF RARE DISEASE | Sell | −5,323 | −$415.30K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 532,976 | $38.53M |
| Nikhil Lalwani | PRESIDENT & CEO | 339,089 | $24.51M |
| Chad Gassert | SVP - CORP. DEV. & STRATEGY | 233,406 | $16.87M |
| Stephen P. Carey | SVP & CFO | 168,993 | $12.22M |
| Christopher Mutz | HEAD OF RARE DISEASE | 91,309 | $6.60M |
| Ori Gutwerg | SVP, GENERICS | 75,534 | $5.46M |
| Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 73,424 | $5.31M |
| Krista Davis | SVP, CHIEF HR OFFICER | 57,033 | $4.12M |
| Patrick D Walsh | Director | 48,432 | $3.50M |
| Thomas Haughey | Director | 40,878 | $2.96M |
| Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 38,271 | $2.77M |
| Renee P Tannenbaum | Director | 29,514 | $2.13M |
| Antonio R Pera | Director | 27,017 | $1.95M |
| Jeanne Thoma | Director | 26,762 | $1.93M |
| Matthew J Leonard | Director | 11,221 | $811.17K |
| Henry O Gosebruch | Director | 6,662 | $481.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANIP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.